The Oxford Science Park

Find Out The Latest

Keep in touch with news and developments from The Oxford Science Park and its occupiers here.

You can also follow us on LinkedIn

Evox Therapeutics Expands Scientific Advisory Board

18 Jul 2025

Evox Therapeutics Ltd, a biotechnology company developing innovative therapies for rare, genetically driven neurodegenerative diseases using a next-generation gene editing modality, today announced the appointment of three world-class scientists to its Scientific Advisory Board (SAB). These appointments come as Evox advances a focused pipeline of transformative gene editing therapies targeting the MSH3 gene for the treatment of Huntington’s... Read more

Ochre Bio appoints Quin Wills as CEO

02 Jul 2025

Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease based at The Oxford Science Park, has appointed Dr Quin Wills as CEO. As Founder of Ochre Bio, and previously CSO, Quin has been driving the company’s innovative approach to late-stage liver disease, developing potential new therapeutics to target disease progression. Quin will now lead the company in the next phase of its ambitions: progressing new drug... Read more

Oxford Science Park cancer experts honoured at inaugural Cancer Vaccine Awards

02 Jul 2025

Two prominent cancer experts based at The Oxford Science Park have been recognised at the UK’s first-ever Cancer Vaccine Awards Ceremony, which celebrated outstanding contributions to cancer vaccine science and clinical innovation across the country. Professor Lindy Durrant, founder and CSO of Scancell, which is headquartered at The Oxford Science Park, received the Innovation in Cancer Vaccine Development award. Her pioneering breakthroughs... Read more

Exscientia and Recursion Enter Definitive Agreement

13 Aug 2024

Recursion and Exscientia plc have announced the companies have entered into a definitive agreement, combining Recursion, a leading clinical stage technology-enabled biotech company decoding biology to industrialize drug discovery, with Exscientia, a technology-driven clinical stage drug design and development company, committed to creating more effective medicines for patients, faster. Chris Gibson, Co-Founder and CEO of Recursion as well as... Read more

Evox Therapeutics Acquires Exosome AAV Technology and Intellectual Property

20 Jun 2023

IP bolsters Company’s already dominant and broad position with respect to exosome therapeutics Acquisition is in line with long-term strategy to improve exosome-mediated delivery to enable novel gene therapies and gene editors OXFORD, United Kingdom, June 20, 2023 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, has purchased Codiak Biosciences engEx-AAV™ technology platform,... Read more

News